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The electron density and electrostatic potential in an aldose re-
ductase holoenzyme complex have been studied by density func-
tional theory (DFT) and diffraction methods. Aldose reductase is
involved in the reduction of glucose in the polyol pathway by using
NADPH as a cofactor. The ultra-high resolution of the diffraction
data and the low thermal-displacement parameters of the struc-
ture allow accurate atomic positions and an experimental charge
density analysis. Based on the x-ray structural data, order-N DFT
calculations have been performed on subsets of up to 711 atoms in
the active site of the molecule. The charge density refinement of
the protein was performed with the program MOPRO by using the
transferability principle and our database of charge density pa-
rameters built from crystallographic analyses of peptides and
amino acids. Electrostatic potentials calculated from the charge
density database, the preliminary experimental electron density
analysis, DFT computations, and atomic charges taken from the
AMBER software dictionary are compared. The electrostatic comple-
mentarity between the cofactor NADP1 and the active site shows
up clearly. The anchoring of the inhibitor is due mainly to hydro-
phobic forces and to only two polar interaction sites within the
enzyme cavity. The potentials calculated by x-ray and DFT tech-
niques agree reasonably well. At the present stage of the refine-
ment, the potentials obtained directly from the database are in
excellent agreementwith the experimental ones. In addition, these
results demonstrate the significant contribution of electron lone
pairs and of atomic polarization effects to the host and guest
mechanism.
We recently showed that accurate electron density analysesmay be carried out on proteins if ultra-high-resolution
data are available (1). Experimental charge density methods
(2–4) give an analytical representation of the valence electron
density (5) from the refinement of nonspherical atomic scatter-
ing factors (program MOPRO, which was developed by us for this
work and is available from C.J., B.G., or C.L.) (6). Electron
density multipoles taken from our oligopeptide charge density
database (7) are the necessary starting parameters to perform a
protein charge density analysis. Therefore, any property depend-
ing on the static charge density may be computed (8): one of the
properties of greatest importance for drug design and biochem-
istry in general is the electrostatic potential, which provides
information about reactivity (9). Correspondingly, order-N den-
sity functional theory (DFT)methods may be used for estimating
precisely the valence charge density and the related properties of
proteins and large molecules (10, 11).
Podjarny and collaborators (12, 13) have recently collected
accurate diffraction intensities to ultra-high resolution (0.66 Å)
on an enzymatic complex: aldose reductase (AR) plus NADP1
plus inhibitor IDD594 (Fig. 1). This system gives a unique
opportunity to test the accuracy of theoretical methods for
calculating the electrostatic potential in protein complexes com-
pared with experiment and vice versa. Therefore, we report on
the crystallographic and DFT electrostatic properties of the AR
complex, a 315-aa protein involved in diabetic complications,
studied largely for the purpose of inhibitor development.
AR is involved in the reduction of glucose to sorbitol using
NADPH as a cofactor.When there is an abnormal glucose excess
in tissues, the accumulation of sorbitol leads to biochemical
alterations that can result in lesions (14). This study contributes
to the search for inhibitors for the pharmacotherapy of diabetic
complications through the analysis of electrostatic forces in the
cofactor and inhibitor binding. For the first time, the host–guest
mechanism is analyzed at a detailed level that goes beyond usual
structural and steric features. The contribution of atomic polar-
ization effects on the electrostatic complementarity of the
protein active site with its ligands will be demonstrated
by ultra-high-resolution crystallography and order-N DFT
methods.
Materials and Methods
The crystallization of human AR was described by Podjarny and
colleagues (12). The crystals are monoclinic, space group P21
(a5 49.43, b5 66.79, c5 47.40 Å, b5 92.40°, one molecule per
asymmetric unit). The 0.66-Å resolution diffraction data of the
AR–NADP1–IDD594 complex (Fig. 1) were collected at 100 K
on the ID19 beamline at the Advanced Photon Source (Argonne,
IL) (13). A total of 2,262,072 reflections have been measured
from two crystals and were merged with program SCALEPACK
(15) to 511,265 unique reflections [Rint(I) 5 2.9% and 2.7% for
crystals 1 and 2]. Eighty percent of the merged reflections have
their intensities .3s. The completeness of the data is 89%
(0.66, d, 20 Å). The structure was first determined by Cachau
et al. (13) using the SHELXL-97 program (16). The hydrogen atoms
in the active site area were all visible in the electron density
maps. The refined protein structure model includes all of the
protein-ligand hydrogen atoms and 629 water molecules.
The charge density refinement strategy with MOPRO (6) was as
follows. The starting position and thermal parameters were those
of Cachau et al. (13), and the initial charge density parameters
were those of neutral spherical atoms. Because the thermal
motion in some parts of the protein (especially in the N- and
C-terminal parts) does not allow a charge density analysis, a
subset of the structure was selected, based on atomic equivalent
thermal B factors ,8 Å2 (see Fig. 2). This charge-density-
refinement substructure included all main-chain atoms, except
the three N-terminal and three C-terminal amino acids and
the Trp-219–Ser-226, Glu-229–Asp-230, and Phe-276–Val-297
residue ranges.
Abbreviations: DFT, density functional theory; AR, aldose reductase; MUL, electrostatic
potential obtained from multipolar refinement; TRF, electrostatic potential obtained
directly from multipolar data base; AMB, electrostatic potential obtained from the AMBER
dictionary.
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At first, a high-order spherical atom refinement was per-
formed with MOPRO (6) on the nonhydrogen atoms of the
substructure, to start the electron density refinement with the
least biased positional and thermal parameters. This refinement
was performed against high-resolution shells of decreasing size.
The three successive resolution ranges used were 0.5–0.76 Å21
(327,546 reflections), 0.6–0.76 Å21 (216,984), and 0.65–0.76 Å21
(152,454). A zero intensity over sigma cutoff, which corresponds
to a completeness of 68% for the highest resolution
shell (0.7–0.76 Å21), was applied. The high-order refinement
strategy consisted of alternate refinement of positional and
anisotropic thermal motion parameters, without any stereo-
chemical or dynamical restraints, until total convergence, for
each of the three resolution ranges. In each case, significant
improvements in the agreement factors R(F) and Rfree(F) were
observed. For example, in the 0.6–0.76 Å21 range, the R(F)
[Rfree(F)] factor dropped from 12.68% (13.42%) to 12.23%
(13.31%).
In the second stage of refinement, the starting electron density
parameters were transferred from our nonspherical atoms mul-
tipole database (7) describing all of the chemical groups present
in proteins. All atoms of the protein were assigned nonspherical
scattering factors; water molecules were modeled as free oxygen
atoms. The starting parameters for NADP1 were from the
charge density analysis of NAD1 (11), and spherical atom
scattering factors were used for the IDD594 inhibitor compound.
All hydrogen atoms were displaced along the XOH bonds to
standard bond distances obtained by neutron diffraction studies
(17) and were subsequently kept fixed.
The transfer procedure led to an immediate improvement of
statistical agreement indices, with the R(F) factor dropping from
11.45% to 11.05% and Rfree(F) from 12.07% to 11.77% for
467,214 reflections with IysI . 0 and 0 , s , 0.76 Å21. This
decrease of the crystallographic R-factors, and the improvement
of the resulting residual density, fully justify the multipolar
parameters transfer procedure.
The electron density refinement was performed with MOPRO
for the main-chain atoms (including hydrogen atoms) of the
substructure described above, against the 456,477 reflections in
the 0.15- to 0.76-Å21 resolution range. For the atoms of the
protein side chains, of the ligands and of the water molecules,
only positions and thermal parameters were refined. This charge
density analysis included the refinement of the multipolar pa-
rameters and the valence populations. Electron density con-
straints were applied, taking advantage of the chemical equiv-
alence of the peptide units. Local symmetry constraints were
also applied, because only the nonzero multipole parameters of
the databank were allowed to vary.
The low-resolution truncation makes some allowance for the
problem of the disordered solvent, because an exponential scaling
model turned out not to be helpful at this stage of our study. One
of the next improvements of the procedure will be to perform the
bulk solvent correction using the flat solvent model (18).
This preliminary charge density refinement led to a descrip-
tion of the average electron density and atomic charges along the
main chain, which was subsequently used for a computation of
the electrostatic potential obtained from multipolar refinement
(MUL) (6). The resulting set of valence population parameters
(Pv) for the protein main-chain atoms are as follows: Ca, 4.04 (7);
O, 6.32 (8); N, 5.12 (7); C, 4.09 (7); Ha, 0.86 (9); HN, 0.81 (8)
[R(F) factor drops from 10.21% to 10.10% and Rfree(F) from
11.04% to 10.68% in the 0.15- to 0.76-Å21 resolution range]. The
experimental charge density refinement of the AR complex is
still being completed and will be reported in detail in a forth-
coming paper.
DFT Calculations. All calculations were performed at the experi-
mental geometry with the DFT program SIESTA (19, 20). This
software allows calculations that scale linearly with, rather than
with the cube of, the number of atoms in the system. This allowed
the study of large parts of the AR complex. Some of the
approximations made are described in this article, and a detailed
description can be found in refs. 19–21.
Exchange and correlation of the Kohn–Sham theory (22) are
treated with the generalized gradient approximation functional
proposed by Perdew et al. (23). Core electrons were replaced by
scalar-relativistic norm-conserving pseudopotentials generated
using the Troullier–Martins scheme (24) in their fully nonlocal
formulation (25). A uniformmesh with a plane-wave cutoff of 75
Ry was used to represent the Hartree and exchange-correlation
potentials and the local part of the pseudopotential.
Valence electrons were described using a basis set of finite-range
numerical atomic orbitals. Radial parts of these orbitals are based
on the scheme of pseudoatomic orbitals of Sankey and Niklewski
(26), who proposed a scheme to build single-z bases. In SIESTA, the
bases are generalized to arbitrarily complete bases up to double-z
with polarization orbitals (21). The orbital confinement energies
used were defined in an earlier report (10), in which the final set of
cutoff values was selected so the electronic density would be
Fig. 1. Ribbon view of the AR-NADP1 inhibitor complex (Left) and chemical
formula of the inhibitor IDD594 (Right).
Fig. 2. View of AR backbone structure with NADP1 and inhibitor repre-
sented in the same orientation as Fig. 1. Amino acids are colored according to
their average equivalent temperature factor. Blue,Beq,4 Å2; green, 4,Beq,
6 Å2; orange, 6 , Beq , 8 Å2; red, Beq . 8 Å2.
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comparable to the experimental density in the database. Use of
these finite-range orbitals, which give rise to sparse overlap and
Hamiltonian matrices, and of pseudo potentials in the Kleinman–
Bylander factorized form, allows the Kohn–Sham Hamiltonian to
be built with order-N operations. More details on these techniques
are given in refs. 19–21.
The DFT quantum chemical modeling included (i) a substruc-
ture consisting of 64 amino acid residues that surround the active
site: 18–22, 42–49, 76–81, 109–116, 121–123, 129–131, 158–161,
182–184, 208–215, 297–312, and HOH464 (603 atoms); (ii) a
substructure consisting of the 64 active-site residues plus the
NADP1 cofactor (676 atoms); and (iii) a substructure including
the same residues, plus the NADP1 cofactor and the IDD594
inhibitor (711 atoms).
For these calculations, the atomic positions were held fixed at
the crystallographic geometry. The 64 aa in the DFT-calculation
substructure completely surround the cofactor NADP1 nicotin-
amide moiety and the inhibitor.
Electrostatic Potential. The experimental electrostatic potentials
were computed from the electron density at the refined geom-
etry with ELECTROS (27) in two ways: first [electrostatic potential
obtained directly from multipolar data base (TRF) (7)], using
directly the charge density parameters transferred from the
multipolar atoms database (7, 28); and, second (MUL), using the
parameters obtained from the preliminary multipole refinement
of the protein main-chain atoms. The experimental potential of
NADP1 was derived from the NAD1 charge density analysis
reported previously (11).
The theoretical DFT potential was obtained from the SIESTA
calculations. For the analysis of the binding interactions, the
electrostatic potential of the cofactor NADP1, of the inhibitor,
and of the enzyme active site were computed separately in vacuo
without any interaction and compared with the electrostatic
potential generated by the complex.
For the sake of comparison, the electrostatic potential ob-
tained from the AMBER dictionary (AMB) generated by the
protein without the cofactor was computed by using the point
charges force field of the AMBER dictionary (29).
The electrostatic potential generated by the protein was
computed in all cases using the 64-aa substructure surrounding
the active site (603 atoms).
Results
Quality of the TRF. The electrostatic potential generated by the
NADP1 cofactor is shown in Fig. 3. The DFT and TRF compare
well around the nicotinamide moiety, whereas the negative
potential around the pyrophosphate group of NADP1 appears
significantly stronger in the TRFmap than in the theoretical one.
The potential in the protein active site obtained by DFT is
compared with the transferred experimental TRF obtained
directly from the charge density database in Figs. 4 a and b, 5 b
and c, and 6 b and d. The agreement between the DFT and TRF
maps is generally good: the positive and negative potential
regions are similar, but the TRF negative potential wells are
generally deeper.
This good agreement demonstrates that a TRF calculated (at
small computing cost) using the database of charge and multi-
pole parameters (7) and high-resolution (d , 1.5 Å) crystallo-
graphic atomic positions (including hydrogen atoms) is very
Fig. 3. Electrostatic potential generated by the NADP1 cofactor in the plane
of the nicotinamide ring. (Left) Experimental. (Right) Theoretical. Contour
levels are60.05 eyÅ. Blue, positive; red, negative; black dotted line, zero level.
Fig. 4. Electrostatic potential generated by the apoenzyme in the active site. The projection plane is the same as in Fig. 3. (a) DFT. (b) TRF. (c) MUL. (d) Point
charges (AMBER).
Fig. 5. Electrostatic potentials in the C6H4Br plane. (a) DFT (inhibitor alone).
(b) DFT (apoenzyme). (c) TRF (apoenzyme). (d) MUL (apoenzyme).
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reliable, and can be obtained routinely as soon as a high-
resolution structure with hydrogen atoms is available.
Electrostatic Complementarity of Ligand–Protein Interactions.
NADP1 is naturally bound by AR to enable sugar hydroxyl
reduction. Although, in the crystal studied, the ligand is not a
sugar but an inhibitor, it is likely that NADP1 interacts in a very
similar way with the protein. The cofactor is made of five
functional groups, namely, nicotinamide, ribose, pyrophosphate,
ribose, and adenine. In the studied complex, the first three
groups are buried within the active site, whereas the last two are
partly outside of the protein, solvated by water molecules.
The NADP1 cofactor alone displays a large negative potential
around the pyrophosphate group (DFT,20.28 eyÅ; TRF,20.40
eyÅ) near the pyrophosphate oxygen atoms, and a positive poten-
tial around the nicotinamide ring due to the global positive charge
of the protonated base (Fig. 3). The oxygen of the NADP1 amide
group generates a small negative potential (DFT,20.04 eyÅ; TRF,
20.04 eyÅ3). The zero-level contour is very similar for the two
methods. Fig. 4 shows the electrostatic potential in the nicotinamide
ring plane generated by the apoenzyme alone calculated by the
DFT, TRF, andMULmethods and from the AMBER point charges
(AMB). As discussed previously, MUL and TRF are in excellent
agreement.
In comparison with Fig. 3, DFT, MUL, and TRF apoenzyme
electrostatic potentials clearly display genuine complementarity
with the NADP1 potential. To each negative potential region
around the cofactor (pyrophosphate group and amide oxygen
atom) corresponds a positive potential region in the active site:
the enzyme positive regions are located near Pro-211 and
Ser-210 (Fig. 4) (DFT,10.34; TRF,10.18; MUL,10.14; AMB,
10.14 eyÅ) and near Asn-160-NH2 and His-110 N«2–H«2 (DFT,
10.20; TRF, 10.26; MUL, 10.12; AMB, 10.06 eyÅ).
Fig. 4 also reveals two negative potential wells: one close to
Cys-298 Sg (DFT,20.18 eyÅ; TRF,20.06 eyÅ; MUL,20.08 eyÅ;
AMB, 20.04 eyÅ) and the second one near Asp-43-Od1 (DFT,
20.28 eyÅ;TRF,20.14 eyÅ;MUL,20.14 eyÅ;AMB,20.18 eyÅ).
In the enzyme–cofactor interaction, these two negative potential
regions complement the strong positive potential of NADP1. The
second of the two negative potential wells is created by a special
configuration of at least 10 protein atoms: one sulfur atom (Cys-298
Sg) and nine oxygen atoms (Cys-298 O, Tyr-209 OH, Gln-183 O«1
and O, Asp-43 Od1, Od2 and O, and Thr-19 O and Og1), of which
all are nearly located in a plane almost perpendicular to the
nicotinamide ring. An important point is that most of these atoms
do not interact directly with NADP1. Only three of them form
hydrogen bondswithNADP1: Cys-298 Sg, Asp-43Od1, andGln-183
O (Fig. 2 and Table 1). It is clear that all other atoms contribute
through long-range electrostatic attraction to the binding of the
cofactor. These results demonstrate that considering only the
short-range H bonds involved in the ligand binding clearly under-
estimates the interaction strength.
Although there is a qualitative agreement among the four
techniques of potential computation, some differences remain. A
significant one is that the AMBER charges yield a weaker negative
potential near Cys-298 Sg. Also, all of the positive AMB potentials
seem to be lower than the DFT, TRF, and MUL values. The
similarity of DFT, TRF, and MUL indicates that they are more
precise than point-charge point potentials, apparently because they
take into account a certain degree of atomic polarization. Further
crystallographic refinement of the side chains, includingCys-298 Sg,
will further clarify this point.
Inhibitor–Active Site Interactions. The chemical structure of the
IDD594 inhibitor (Fig. 1) differs significantly from that of
glucose, but the inhibitor carboxylate group should bind in a
similar region of the enzyme active site as the reacting hydroxyl
group of glucose (13, 14). Because no high-resolution data exist
for the glucose complex, the discussion will focus on inhibitor
interactions. The charge density refinement of the inhibitor was
done ab initio, because of the lack of multipole values in the
database for the specific chemical groups. Therefore, the
IDD594 electrostatic potentials displayed in the present study
are derived from the DFT calculations only. Fig. 5 gives the DFT
Fig. 6. Electrostatic potentials in the Br. . . OG1-HG1 region. All projection
planes contain the Br and OG1-HG1 atoms. (a) DFT (inhibitor alone). (b) DFT
(apoenzyme). (c) DFT (AR complex). (d) TRF (apoenzyme).
Table 1. Distances and angles of the hydrogen bonds involving
NADP1 or the inhibitor
Acc. . . Donor AD, Å DHA, °
IDD594–IDD594
O34. . . N17 2.984 (9) 174
IDD594–protein
O33. . . OHoY48 2.731 (6) 174
O33. . . Nd2oH110 2.667 (6) 159
O34. . . N«1oW111 3.068 (8) 154
NADP1–protein
O15. . . NoT19 3.248 (6) 152
All others
O16. . . NoW20 2.906 (6) 137
O11. . . NzoK21 2.827 (7) 150
O17. . . Nd2oN160 2.887 (7) 165
O12. . . OgoS210 2.803 (7) 167
O29. . . OgoS263 2.669 (9) 159
O27. . . NzoK262 2.751 (9) 171
O22. . . NoK262 2.861 (7) 173
O29. . . NH1oR268 3.028 (9) 162
N25. . . Nd2oN272 3.030 (11) 173
OoW584. . . O25 2.680 (12) 165
Od2oD43. . . O15 2.682 (6) 147
OgoS159. . . N12 2.847 (7) 140
O«1oQ183. . . N12 2.904 (5) 165
O«1oQ183. . . C20 3.038 (7) 136
O«2oE271. . . N24 2.940 (15) 156
Od1oN272. . . N24 2.860 (14) 148
The standard deviation between non-H atoms is given in parentheses.
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potential generated by the inhibitor. Except for the carboxylate
group, the potential is slightly positive without any large exten-
sion, reflecting the hydrophobic nature of the compound. An
orthogonal view (not shown) gives similar information, except a
slightly negative well (DFT value, 20.02 eyÅ) in the vicinity of
the Br-bearing aromatic ring leading to a p–p interaction with
Trp-111. This contrasts with the binding of NADP1, which is
strongly electrostatic. Fig. 5 also shows that the corresponding
cavity of the apoenzyme displays an overall low positive poten-
tial, with two negative wells created by Cys-80 Sg and the Thr-113
hydroxyl group (DFT, 20.1 eyÅ; TRF, 20.2 eyÅ; MUL, 20.25
eyÅ). The experimental MUL and TRF maps give a negative
potential around Tyr-309 (TRF and MUL,20.10 eyÅ), whereas
the theoretical value is slightly positive (DFT, 10.02 eyÅ).
The bromine atom of the inhibitor forms an exceptionally short
contact with the Og1 oxygen atom of Thr-113 (distance, 3.0 Å). As
pointed out by Podjarny and colleagues (30), this is the shortest
Br. . .O contact observed so far according to the Cambridge Struc-
tural Database (31). Fig. 6 shows the potential around the bromine
atom, within the protein complex, for the ligand alone, and for the
active site. The hydroxyl hydrogen atom of the Thr-113 is not
directed toward the bromine atom, as might have been expected,
but is involved instead in a hydrogen bond with the Thr-113
main-chain carbonyl (30). The negative potential due to the lone
pairs of Og1 of Thr-113 can be directly superposed with the positive
potential developed by the bromine atom of the inhibitor; this
renders this short interaction essentially electrostatic. The theoret-
ical deformation density maps also reveal effects of the interaction
on the bromine with oxygen atom nonbonding electron density
(Fig. 7a, shown in the same plane as Fig. 6). The orthogonal views
of the torus-shaped deformation density around the Br atom (Fig.
7 b and c), for the ligand alone and in the complex, reveal the effects
of the interaction on the bromine atom. Through the interaction
with the Og1 of Thr-113, the bromine atom is polarized and loses
its cylindrical symmetry.
The second polar interaction site of the ligand is located on the
other side of themolecule (Fig. 1). Fig. 8 displays theDFT potential
generated in the carboxylate plane by the ligand alone (a), by the
apoenzyme active site (b), and by the complex (c). Fig. 8d shows
theTRFgenerated by the apoenzyme. The carboxylate groupof the
inhibitor interacts with the enzyme by means of three hydrogen
bonds; it also accepts an intramolecular hydrogen bond (Table 1).
For both oxygen atoms O34 and O33, the electron lone pairs are
approximately located on the direction between acceptor and
donor atoms. Such directional effects on hydrogen bonding around
the oxygen atoms are better described by a multipolar atom model
than by atomic point charges.
The DFT electrostatic potentials in the plane perpendicular to
Fig. 8. Electrostatic potentials shown in the inhibitor carboxylate plane. (a)
DFT (inhibitor alone). (b) DFT (apoenzyme). (c) DFT (AR complex). (d) TRF
(apoenzyme).
Fig. 9. Electrostatic potentials shown in the plane perpendicular to the
inhibitor carboxylate. (a) DFT (protein alone). (b) DFT (inhibitor alone). (c) DFT
(protein plus NADP1). (d) TRF (protein plus NADP1).
Fig. 7. Theoretical deformation density maps of the Br. . . OG1-Thr-113 region in the complex and alone. (a) Map in the Br. . . OOH plane. Also shown are maps
displaying the bromine deformation density of toric shape in the plane perpendicular to the COBr bond in the complex (b) and for the inhibitor alone (c).
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the inhibitor carboxylate are represented around the ligand alone
(Fig. 9b), in the active site of the protein alone (Fig. 9a) and in the
active site of the protein–NADP1 complex (Fig. 9c); the corre-
sponding TRF is given Fig. 9d. Both Figs. 8 and 9 show the good
agreement between experimental and theoretical active site poten-
tials, which confirms the feasibility of interaction analyses using the
database and high-resolution x-ray refinement only. There is a local
complementarity between the potentials; in addition, several elec-
trostatic potential saddle points, characteristic of H-bonds, can be
observed. The potential in the plane perpendicular to the inhibitor
carboxylate (Fig. 9) shows that the attraction of the ligand carbox-
ylate requires the presence of the NADP1 cofactor. The positively
charged nicotinamide group contributes to the electrostatic
complementarity and therefore to the anchoring of the inhibitor
carboxylate (Fig. 9 c and d). Indeed, without the cofactor (Fig. 9a),
the protein active site displays a large negative potential that would
hinder the binding of COO2 (Fig. 9b).
Discussion and Conclusion
Obtaining accurate electrostatic properties to understand inter-
actions among proteins, ligands, and cofactors is very challenging
and has many potential applications in life sciences, as shown by
the increasing number of publications devoted to this topic. First,
this research needs atomic resolution diffraction data to be able
to locate and refine the hydrogen atoms of the active site. The
use of dipolar scattering factors for hydrogen atoms, as defined
in our database, is necessary. Recent developments of diffraction
techniques at third-generation synchrotrons (32) and progress in
cryocrystallography (33) and protein crystallization promise
more high-resolution data, which will require nonspherical atom
models to yield more accurate atomic coordinates and thermal-
displacement parameters. This will also permit more precise
location of molecules and ions with important roles in bioelec-
trostatics in the protein solvation shell. Given a well refined
high-resolution structure, electrostatic properties may be calcu-
lated in different ways: directly by multipolar analysis or using
DFT (this work) andyor QMyMM methods (34–36) or by using
fragments experimentally (TRF; ref. 27 and this work) or
theoretically calculated (37–41), or by point charge models such
as AMBER (29), CHARMM (42), or GRASP (43).
This paper has demonstrated that DFT quality potentials can
be obtained quickly and almost routinely from high-resolution
diffraction data (TRF). Such a calculation can be routinely
performed, at very low cost, with any protein structure at atomic
resolution. An application of these methods to allosteric insulin
hexamers is under way (R. H. Blessing, G. D. Smith, E. Ciszak,
W. A. Pangborn, B.G., and C.L., unpublished data). A direct
determination from an accurate experimental charge distribu-
tion transfer plus refinement is also possible, as shown in this
paper (MUL). But this latter possibility still needs further testing
and development tests to define the best refinement strategies
(even though the refinement program MOPRO is available) to
ensure that the resulting potential is more accurate than the
database-transferred one. This issue will be discussed in a
forthcoming publication.
Concerning the complex AR–NADP1 inhibitor, and enzy-
mology more generally, this work reports, for the first time to our
best knowledge, an experimental and theoretical analysis of the
protein host–guest interaction at the electrostatic level, i.e.,
beyond geometrical or putative hydrogen bonding consider-
ations. The roles of coulombic long-range interactions and of
atomic polarizability have been clearly evidenced in the AR–
cofactor complex. The results show remarkable electrostatic
apoenzyme–cofactor complementarity within the active site,
and good hydrophilicyhydrophobic complementarity between
the enzyme and the inhibitor. The carboxylate group of the
inhibitor is the source of the main polar interaction with
the enzyme, and the electrostatic complementarity is with the
positive potential produced by the NADP1 cofactor. In addition,
the polarizable bromine atom of the inhibitor forms a short polar
contact with an hydroxyl oxygen atom.
Further work is planned with AR to develop optimal charge
density refinement and potential mapping strategies, and to eval-
uate apoenzyme–cofactor–ligand electrostatic interaction energies.
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